Chitosan-Coated PLGA Nanoparticles Encapsulating Triamcinolone Acetonide as a Potential Candidate for Sustained Ocular Drug Delivery
The current treatment for the acquired retinal vasculopathies involves lifelong repeated intravitreal injections of either anti-vascular endothelial growth factor (VEGF) therapy or modulation of inflammation with steroids. Consequently, any treatment modification that decreases this treatment burden...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/13/10/1590 |
| _version_ | 1797513440641679360 |
|---|---|
| author | Madhuri Dandamudi Peter McLoughlin Gautam Behl Sweta Rani Lee Coffey Anuj Chauhan David Kent Laurence Fitzhenry |
| author_facet | Madhuri Dandamudi Peter McLoughlin Gautam Behl Sweta Rani Lee Coffey Anuj Chauhan David Kent Laurence Fitzhenry |
| author_sort | Madhuri Dandamudi |
| collection | DOAJ |
| description | The current treatment for the acquired retinal vasculopathies involves lifelong repeated intravitreal injections of either anti-vascular endothelial growth factor (VEGF) therapy or modulation of inflammation with steroids. Consequently, any treatment modification that decreases this treatment burden for patients and doctors alike would be a welcome intervention. To that end, this research aims to develop a topically applied nanoparticulate system encapsulating a corticosteroid for extended drug release. Poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) supports the controlled release of the encapsulated drug, while surface modification of these NPs with chitosan might prolong the mucoadhesion ability leading to improved bioavailability of the drug. Triamcinolone acetonide (TA)-loaded chitosan-coated PLGA NPs were fabricated using the oil-in-water emulsion technique. The optimized surface-modified NPs obtained using Box-Behnken response surface statistical design were reproducible with a particle diameter of 334 ± 67.95 to 386 ± 15.14 nm and PDI between 0.09 and 0.15. These NPs encapsulated 55–57% of TA and displayed a controlled release of the drug reaching a plateau in 27 h. Fourier-transform infrared spectroscopic (FTIR) analysis demonstrated characteristic peaks for chitosan (C-H, CONH2 and C-O at 2935, 1631 and 1087 cm<sup>−1</sup>, respectively) in chitosan-coated PLGA NPs. This result data, coupled with positive zeta potential values (ranged between +26 and +33 mV), suggests the successful coating of chitosan onto PLGA NPs. Upon coating of the NPs, the thermal stability of the drug, polymer, surfactant and PLGA NPs have been enhanced. The characteristics of the surface-modified NPs supports their use as potential candidates for topical ocular drug delivery for acquired retinal vasculopathies. |
| first_indexed | 2024-03-10T06:16:37Z |
| format | Article |
| id | doaj.art-cb41676a59804b09bcfd52f566a77e97 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-10T06:16:37Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-cb41676a59804b09bcfd52f566a77e972023-11-22T19:38:06ZengMDPI AGPharmaceutics1999-49232021-09-011310159010.3390/pharmaceutics13101590Chitosan-Coated PLGA Nanoparticles Encapsulating Triamcinolone Acetonide as a Potential Candidate for Sustained Ocular Drug DeliveryMadhuri Dandamudi0Peter McLoughlin1Gautam Behl2Sweta Rani3Lee Coffey4Anuj Chauhan5David Kent6Laurence Fitzhenry7Ocular Therapeutics Research Group, Pharmaceutical and Molecular Biotechnology Research Centre, Waterford Institute of Technology, X91 K0EK Waterford, IrelandOcular Therapeutics Research Group, Pharmaceutical and Molecular Biotechnology Research Centre, Waterford Institute of Technology, X91 K0EK Waterford, IrelandOcular Therapeutics Research Group, Pharmaceutical and Molecular Biotechnology Research Centre, Waterford Institute of Technology, X91 K0EK Waterford, IrelandOcular Therapeutics Research Group, Pharmaceutical and Molecular Biotechnology Research Centre, Waterford Institute of Technology, X91 K0EK Waterford, IrelandOcular Therapeutics Research Group, Pharmaceutical and Molecular Biotechnology Research Centre, Waterford Institute of Technology, X91 K0EK Waterford, IrelandDepartment of Chemical and Biological Engineering, Colorado School of Mines, Colorado, CO 80401, USAThe Vision Clinic, R95 XC98 Kilkenny, IrelandOcular Therapeutics Research Group, Pharmaceutical and Molecular Biotechnology Research Centre, Waterford Institute of Technology, X91 K0EK Waterford, IrelandThe current treatment for the acquired retinal vasculopathies involves lifelong repeated intravitreal injections of either anti-vascular endothelial growth factor (VEGF) therapy or modulation of inflammation with steroids. Consequently, any treatment modification that decreases this treatment burden for patients and doctors alike would be a welcome intervention. To that end, this research aims to develop a topically applied nanoparticulate system encapsulating a corticosteroid for extended drug release. Poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) supports the controlled release of the encapsulated drug, while surface modification of these NPs with chitosan might prolong the mucoadhesion ability leading to improved bioavailability of the drug. Triamcinolone acetonide (TA)-loaded chitosan-coated PLGA NPs were fabricated using the oil-in-water emulsion technique. The optimized surface-modified NPs obtained using Box-Behnken response surface statistical design were reproducible with a particle diameter of 334 ± 67.95 to 386 ± 15.14 nm and PDI between 0.09 and 0.15. These NPs encapsulated 55–57% of TA and displayed a controlled release of the drug reaching a plateau in 27 h. Fourier-transform infrared spectroscopic (FTIR) analysis demonstrated characteristic peaks for chitosan (C-H, CONH2 and C-O at 2935, 1631 and 1087 cm<sup>−1</sup>, respectively) in chitosan-coated PLGA NPs. This result data, coupled with positive zeta potential values (ranged between +26 and +33 mV), suggests the successful coating of chitosan onto PLGA NPs. Upon coating of the NPs, the thermal stability of the drug, polymer, surfactant and PLGA NPs have been enhanced. The characteristics of the surface-modified NPs supports their use as potential candidates for topical ocular drug delivery for acquired retinal vasculopathies.https://www.mdpi.com/1999-4923/13/10/1590nanoparticlesposterior segment eye diseasesPLGAchitosanchitosan-coated nanoparticlestriamcinolone acetonide |
| spellingShingle | Madhuri Dandamudi Peter McLoughlin Gautam Behl Sweta Rani Lee Coffey Anuj Chauhan David Kent Laurence Fitzhenry Chitosan-Coated PLGA Nanoparticles Encapsulating Triamcinolone Acetonide as a Potential Candidate for Sustained Ocular Drug Delivery Pharmaceutics nanoparticles posterior segment eye diseases PLGA chitosan chitosan-coated nanoparticles triamcinolone acetonide |
| title | Chitosan-Coated PLGA Nanoparticles Encapsulating Triamcinolone Acetonide as a Potential Candidate for Sustained Ocular Drug Delivery |
| title_full | Chitosan-Coated PLGA Nanoparticles Encapsulating Triamcinolone Acetonide as a Potential Candidate for Sustained Ocular Drug Delivery |
| title_fullStr | Chitosan-Coated PLGA Nanoparticles Encapsulating Triamcinolone Acetonide as a Potential Candidate for Sustained Ocular Drug Delivery |
| title_full_unstemmed | Chitosan-Coated PLGA Nanoparticles Encapsulating Triamcinolone Acetonide as a Potential Candidate for Sustained Ocular Drug Delivery |
| title_short | Chitosan-Coated PLGA Nanoparticles Encapsulating Triamcinolone Acetonide as a Potential Candidate for Sustained Ocular Drug Delivery |
| title_sort | chitosan coated plga nanoparticles encapsulating triamcinolone acetonide as a potential candidate for sustained ocular drug delivery |
| topic | nanoparticles posterior segment eye diseases PLGA chitosan chitosan-coated nanoparticles triamcinolone acetonide |
| url | https://www.mdpi.com/1999-4923/13/10/1590 |
| work_keys_str_mv | AT madhuridandamudi chitosancoatedplgananoparticlesencapsulatingtriamcinoloneacetonideasapotentialcandidateforsustainedoculardrugdelivery AT petermcloughlin chitosancoatedplgananoparticlesencapsulatingtriamcinoloneacetonideasapotentialcandidateforsustainedoculardrugdelivery AT gautambehl chitosancoatedplgananoparticlesencapsulatingtriamcinoloneacetonideasapotentialcandidateforsustainedoculardrugdelivery AT swetarani chitosancoatedplgananoparticlesencapsulatingtriamcinoloneacetonideasapotentialcandidateforsustainedoculardrugdelivery AT leecoffey chitosancoatedplgananoparticlesencapsulatingtriamcinoloneacetonideasapotentialcandidateforsustainedoculardrugdelivery AT anujchauhan chitosancoatedplgananoparticlesencapsulatingtriamcinoloneacetonideasapotentialcandidateforsustainedoculardrugdelivery AT davidkent chitosancoatedplgananoparticlesencapsulatingtriamcinoloneacetonideasapotentialcandidateforsustainedoculardrugdelivery AT laurencefitzhenry chitosancoatedplgananoparticlesencapsulatingtriamcinoloneacetonideasapotentialcandidateforsustainedoculardrugdelivery |